$21.88
-0.10[-0.45%]
At close: Apr 29
$21.88
0[0.00%]
After Hours: 7:50PM EDT
Intellia Therapeutics
(NASDAQ:NTLA)Intellia Therapeutics Stock (NASDAQ:NTLA), Analyst Ratings, Price Targets, Predictions
Intellia Therapeutics Inc has a consensus price target of $88.19, established from looking at the 96 latest analyst ratings. The last 3 analyst ratings were released from Wedbush, Goldman Sachs, and Canaccord Genuity on April 23, 2024, February 23, 2024, and February 23, 2024. With an average price target of $44.67 between Wedbush, Goldman Sachs, and Canaccord Genuity, there's an implied 104.14% upside for Intellia Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Wedbush
Goldman Sachs
Canaccord Genuity
Wolfe Research
Oppenheimer
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Intellia Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/23/2024 | NTLA | Buy Now | Intellia Therapeutics | $21.88 | 32.54% | Wedbush | David Nierengarten | → $29 | Reiterates | Neutral → Neutral | Get Alert |
| 02/23/2024 | NTLA | Buy Now | Intellia Therapeutics | $21.88 | 46.25% | Goldman Sachs | Salveen Richter | → $32 | Downgrade | Buy → Neutral | Get Alert |
| 02/23/2024 | NTLA | Buy Now | Intellia Therapeutics | $21.88 | 233.64% | Canaccord Genuity | Whitney Ijem | $72 → $73 | Maintains | Buy | Get Alert |
| 02/15/2024 | NTLA | Buy Now | Intellia Therapeutics | $21.88 | — | Wolfe Research | Andy Chen | — | Initiates | → Peer Perform | Get Alert |
| 11/13/2023 | NTLA | Buy Now | Intellia Therapeutics | $21.88 | 219.93% | Oppenheimer | Jay Olson | $80 → $70 | Maintains | Outperform | Get Alert |
| 11/13/2023 | NTLA | Buy Now | Intellia Therapeutics | $21.88 | 288.48% | Morgan Stanley | Terence Flynn | $90 → $85 | Maintains | Overweight | Get Alert |
| 11/10/2023 | NTLA | Buy Now | Intellia Therapeutics | $21.88 | 183.36% | BMO Capital | Kostas Biliouris | $64 → $62 | Maintains | Outperform | Get Alert |
| 11/10/2023 | NTLA | Buy Now | Intellia Therapeutics | $21.88 | 219.93% | RBC Capital | Luca Issi | $80 → $70 | Maintains | Outperform | Get Alert |
| 11/10/2023 | NTLA | Buy Now | Intellia Therapeutics | $21.88 | 521.57% | Goldman Sachs | Salveen Richter | $157 → $136 | Maintains | Buy | Get Alert |
| 11/10/2023 | NTLA | Buy Now | Intellia Therapeutics | $21.88 | 160.51% | Raymond James | Steven Seedhouse | $78 → $57 | Maintains | Outperform | Get Alert |
| 09/13/2023 | NTLA | Buy Now | Intellia Therapeutics | $21.88 | 197.07% | Cantor Fitzgerald | Rick Bienkowski | → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 08/29/2023 | NTLA | Buy Now | Intellia Therapeutics | $21.88 | 197.07% | Cantor Fitzgerald | Rick Bienkowski | → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 08/09/2023 | NTLA | Buy Now | Intellia Therapeutics | $21.88 | 197.07% | Cantor Fitzgerald | Rick Bienkowski | → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 08/07/2023 | NTLA | Buy Now | Intellia Therapeutics | $21.88 | 311.33% | Barclays | Gena Wang | $86 → $90 | Maintains | Overweight | Get Alert |
| 08/07/2023 | NTLA | Buy Now | Intellia Therapeutics | $21.88 | 197.07% | Canaccord Genuity | Whitney Ijem | $66 → $65 | Maintains | Buy | Get Alert |
| 08/07/2023 | NTLA | Buy Now | Intellia Therapeutics | $21.88 | 389.03% | Chardan Capital | Geulah Livshits | → $107 | Reiterates | Buy → Buy | Get Alert |
| 08/04/2023 | NTLA | Buy Now | Intellia Therapeutics | $21.88 | 311.33% | Barclays | Gena Wang | $148 → $90 | Maintains | Overweight | Get Alert |
| 08/04/2023 | NTLA | Buy Now | Intellia Therapeutics | $21.88 | 82.82% | Citigroup | David Lewis | $44 → $40 | Maintains | Neutral | Get Alert |
| 06/13/2023 | NTLA | Buy Now | Intellia Therapeutics | $21.88 | 315.9% | B of A Securities | Greg Harrison | $89 → $91 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Intellia Therapeutics (NTLA)?
The latest price target for Intellia Therapeutics (NASDAQ: NTLA) was reported by Wedbush on April 23, 2024. The analyst firm set a price target for $29.00 expecting NTLA to rise to within 12 months (a possible 32.54% upside). 26 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Intellia Therapeutics (NTLA)?
The latest analyst rating for Intellia Therapeutics (NASDAQ: NTLA) was provided by Wedbush, and Intellia Therapeutics reiterated their neutral rating.
When was the last upgrade for Intellia Therapeutics (NTLA)?
The last upgrade for Intellia Therapeutics Inc happened on March 14, 2023 when BMO Capital raised their price target to $57. BMO Capital previously had a market perform for Intellia Therapeutics Inc.
When was the last downgrade for Intellia Therapeutics (NTLA)?
The last downgrade for Intellia Therapeutics Inc happened on February 23, 2024 when Goldman Sachs changed their price target from N/A to $32 for Intellia Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Intellia Therapeutics (NTLA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Intellia Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Intellia Therapeutics was filed on April 23, 2024 so you should expect the next rating to be made available sometime around April 23, 2025.
Is the Analyst Rating Intellia Therapeutics (NTLA) correct?
While ratings are subjective and will change, the latest Intellia Therapeutics (NTLA) rating was a reiterated with a price target of $0.00 to $29.00. The current price Intellia Therapeutics (NTLA) is trading at is $21.88, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.